GlassScriptPhysician profile
Vanessa M Taylor
NPI 1942235668
$12,305.67
in general payments reported to CMS, 2019-2025
31 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $517 · 2021: $1,445 · 2022: $7,007 · 2023: $1,038 · 2024: $314 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $8,314.71 | 2019-2025 | Stravix, Grafix, Oasis |
| Empire Medical, INC | $1,211.34 | 2021 | |
| Wright Medical Technology, INC. | $594.14 | 2019-2020 | |
| Stryker Corporation | $433.35 | 2021-2025 | Gravity Synchfix, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Paragon 28, INC. | $233.46 | 2019-2022 | |
| Koya Medical, INC. | $204.46 | 2023 | Dayspring |
| Horizon Therapeutics Plc | $181.55 | 2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $156.53 | 2023-2025 | Nuzyra |
| Musculoskeletal Transplant Foundation INC. | $98.77 | 2023 | |
| Zimmer Biomet Holdings, INC. | $86.24 | 2019-2022 | |
| Sebela Pharmaceuticals INC. | $69.53 | 2021-2022 | |
| Averitas Pharma INC. | $65.94 | 2023 | Qutenza |
| Angiodynamics, INC. | $62.69 | 2022 | |
| Mimedx Group, INC. | $59.16 | 2024-2025 | |
| Integra Lifesciences Corporation | $54.81 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.67 | 2019 | |
| Nabriva Therapeutics, Plc | $45.46 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $40.91 | 2025 | Oxistat |
| Amgen INC. | $39.07 | 2024 | Krystexxa |
| Nevro Corp. | $38.42 | 2022-2023 | Senza |
| Medline Industries LP | $36.44 | 2021-2022 | |
| Djo, LLC | $34.47 | 2020 | |
| Tactile Systems Technology INC | $33.55 | 2019-2025 | Flexitouch Plus, Nimbl |
| Depuy Synthes Sales INC. | $29.60 | 2019 | |
| Grt US Holding, INC. | $27.28 | 2022 | |
| Osiris Therapeutics INC. | $22.19 | 2019 | |
| Solventum Corporation | $19.02 | 2024 | Activ.A.C., Promogran Prisma |
| Cardiovascular Systems INC. | $17.79 | 2021 | |
| Melinta Therapeutics, LLC | $16.53 | 2020 | |
| Ermi LLC | $15.06 | 2020 | |
| Zyla Life Sciences, INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.